Getinge reported good Q2 19 numbers – beating top-line estimates and meeting bottom-line estimates. Net sales were up 4% on an organic basis – driven by Acute Care Therapies and Life Sciences. Regionally, the muted performance in EMEA was more than offset by the strength in APAC and the Americas. Adjusted EBIT (SEK 466m) met estimates with the associated margin at 7.4%. Management continues to expect 2-4% organic growth in FY19. Following the good Q2 numbers, we will be raising ou
18 Jul 2019
Strong growth even as product mix hurts the gross margin
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Strong growth even as product mix hurts the gross margin
Getinge AB Class B (GTN:FRA) | 0 0 0.9% | Mkt Cap: 25,911m
- Published:
18 Jul 2019 -
Author:
Virendra Chauhan -
Pages:
3
Getinge reported good Q2 19 numbers – beating top-line estimates and meeting bottom-line estimates. Net sales were up 4% on an organic basis – driven by Acute Care Therapies and Life Sciences. Regionally, the muted performance in EMEA was more than offset by the strength in APAC and the Americas. Adjusted EBIT (SEK 466m) met estimates with the associated margin at 7.4%. Management continues to expect 2-4% organic growth in FY19. Following the good Q2 numbers, we will be raising ou